Welcome to our dedicated page for Biolife Solutions SEC filings (Ticker: BLFS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioLife Solutions SEC filings document material-event disclosures for a Nasdaq-listed life sciences supplier focused on cell processing tools and services for cell and gene therapy. Recent 8-K filings cover unaudited financial results, continuing-operations performance, operational highlights, and Regulation FD investor presentations describing the company’s bioproduction products and CGT market focus.
The filing record also includes governance and corporate-administration disclosures, including stockholder voting results from the annual meeting, director elections, advisory executive compensation votes, auditor ratification, and an officer retirement notice. These filings frame the company’s public reporting around operating results, product-market disclosures, governance matters, and executive-level changes.
BioLife Solutions Inc.'s Chief Financial Officer reported a sale of company stock under a pre-arranged Rule 10b5-1(c) trading plan. On 12/09/2025, the officer sold 1,033 shares of common stock at a price of $25.13 per share. After this transaction, the officer beneficially owned 151,736 shares of BioLife Solutions common stock in direct ownership. The filing explains that the sale was made to satisfy tax withholding obligations related to the vesting of restricted stock.
BioLife Solutions Inc. reported insider share sales by its Chief Human Resources Officer. The officer sold 233 shares of common stock on 12/09/2025 at $25.13 per share and 713 shares on 12/15/2025 at $24.46 per share. After these transactions, the officer beneficially owns 76,006 shares directly. The sales were made under a Rule 10b5-1(c) trading plan adopted effective 03-08-2024 to cover tax withholding obligations from the vesting of restricted stock.
BioLife Solutions Inc. director Amy DuRoss reported a sale of company stock. On 12/15/2025, she sold 2,000 shares of BioLife Solutions common stock at a price of $24.6 per share. After this transaction, she beneficially owned 18,687 shares, held directly.
BioLife Solutions Inc. reported an insider stock sale by its Chief Marketing Officer. On 12/09/2025, the officer sold 358 shares of common stock at a price of $25.13 per share. After this transaction, the officer beneficially owned 132,908 shares in a direct capacity.
The sale was made under a Rule 10b5-1(c) trading plan that the reporting person adopted effective 03-08-2024 to cover tax withholding obligations tied to the vesting of restricted stock. This indicates the transaction was pre-arranged for tax purposes rather than a discretionary open-market sale.
BioLife Solutions Inc. officer Karen A. Foster, Chief Quality and Operations, reported a small stock sale in a Form 4 filing. On 12/09/2025, she sold 519 shares of common stock at $25.13 per share. This transaction was made under a pre-arranged Rule 10b5-1(c) trading plan adopted effective 03-08-2024 to cover tax withholding obligations from the vesting of restricted stock. After this sale, she directly holds 192,319 shares of BioLife Solutions common stock.
BioLife Solutions Inc. (BLFS) reported an insider stock sale by a board director. Director Amy DuRoss filed a Form 4 disclosing three open-market sales of BLFS common stock on 11/19/2025, 11/20/2025, and 11/21/2025. The reported transactions were sales of 477 shares at $24.50, 4,523 shares at $24.51, and 1,000 shares at $26.00, all coded as dispositions. After these trades, DuRoss beneficially owned 24,687 shares of BioLife Solutions common stock in direct ownership.
BioLife Solutions, Inc.
BioLife Solutions (BLFS) disclosed insider stock sales by its President and CEO, who is also a Director. The filing reports three open‑market sales of Common Stock: 35,417 shares at a weighted average price of $26.15 on 11/11/2025; 33,418 shares at $25.88 on 11/12/2025; and 31,165 shares at $25.33 on 11/13/2025.
Following these transactions, the executive’s directly held shares moved from 454,581 to 421,163 and then to 389,998. Each price is a weighted average, with individual trades executed within disclosed ranges.
BioLife Solutions (BLFS) reported Q3 results with total revenue of $28.1 million, up from $21.4 million a year ago, and net income of $0.6 million ($0.01 per share). Operating loss narrowed to $0.09 million, aided by $0.8 million in other income. For the first nine months, revenue was $77.4 million and net loss was $15.7 million, reflecting a $15.5 million IPR&D expense tied to the PanTHERA acquisition.
Cash, cash equivalents, and available-for-sale securities totaled $98.4 million at September 30, 2025. Year-to-date, operating cash flow was $15.2 million, investing used $72.7 million (including marketable securities purchases and IPR&D), and financing used $8.4 million as the company repaid $7.5 million on term loans. Shareholders’ equity was $353.7 million.
Management continues to focus on higher-margin bioproduction products after divesting several businesses in 2024. The company completed the PanTHERA transaction (accounted for as an asset acquisition) and, subsequent to quarter-end, signed an agreement to sell SAVSU, which remains in continuing operations for this period.
BioLife Solutions (BLFS) filed an 8-K announcing Q3 2025 results. The company reported that it issued a press release with unaudited financial results and operational highlights for the quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1.
The filing classifies the update under Item 2.02 (Results of Operations and Financial Condition). BioLife’s common stock trades on the Nasdaq under the symbol BLFS.